SAN DIEGO, California, December 16, 2015 /PRNewswire/ --
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today identification of a series of compounds that have been identified by biochemical testing which interact with the Company’s newly identified immune checkpoint NR2F6. This is the first of a series of steps in developing small molecules which the Company plans to use as a basis for creating “a checkpoint inhibitor pill.” Previously, the Company reported that the use of gene silencing of NR2F6 leads to induction of cancer stem cell differentiation, a process that renders malignant cancer cells benign.
“We are optimistic that these initial positive data will lead the way forward into what we hope will be a new generation of immune stimulatory cancer drugs: Orally-available agents that will on the one hand unleash anticancer immune responses and on the other hand directly reprogram cancers rendering them less malignant,” said Harry Lander, Ph.D., President and Chief Scientific Officer of Regen. “In parallel, we are continuing gene silencing studies with Santosh Kesari, M.D., Ph.D. in which we are precisely quantifying the correlation between inhibition of NR2F6 and immune stimulation. We believe that by using 2 independent approaches towards the same target, we will be in a position to accelerate clinical implementation and diversify our product pipeline.” Dr. Santosh Kesari, a renowned neuro-oncologist who holds a doctorate in molecular biology, is with the John Wayne Cancer Institute at Providence Saint John’s Health Center.
NR2F6 is a molecular switch known as an “orphan nuclear receptor”, which controls genes associated with the immune response as well as genes associated with the ability of cancer stem cells to propagate. Regen has filed numerous patent applications covering means of manipulating NR2F6 in oncology and immunology. Issued US Patent # 9091696B2 was assigned to Regen and covers means of screening small molecules such as the ones identified in the current patent filing.
“From a patient perspective, development of a ‘checkpoint inhibitor pill’ offers numerous potential advantages to currently utilized checkpoint inhibitors in terms of cost, lack of need for injections, and potentially better control of the drug’s activities,” said David Koos, Ph.D., Chairman and CEO of Regen.
About Regen BioPharma, Inc.
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) and (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact:
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
David.koos@regenbiopharma.com
The Dorsee Company
Debra Dorsee
+1-(858)-229-6082
Debbie@thedorseecompany.com
http://www.regenbiopharma.com and
http://www.regenbiopharmainc.com
david.koos@regenbiopharma.com
Twitter: Regen BioPharma News:
https://twitter.com/KoosRegen
SOURCE Regen BioPharma Inc.
